Lecigimon

Levodopa/Carbidopa/Entacapone, the active ingredient in Lecigimon, is a dopamine precursor with COMT inhibitor presented as an oral tablet formulation for intestinal use. It is indicated for the management of Parkinson's disease symptoms in adult patients. The combination enhances central dopamine availability while reducing peripheral metabolism, helping to control motor fluctuations.

GNH USA supplies Lecigimon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across EU and global markets.

Lecigimon, containing levodopa, carbidopa and entacapone, is used in the dopaminergic treatment pathway for Parkinson's disease.

- Parkinson's disease: improves motor control and reduces OFF periods when used with levodopa. - Levodopa‑induced motor fluctuations: prolongs levodopa plasma half‑life to smooth symptom control. - Adjunct therapy in advanced Parkinsonian syndrome: helps maintain consistent dopaminergic stimulation and reduces dosing frequency.

Lecigimon may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: often related to orthostatic changes. - Insomnia: difficulty falling or staying asleep. - Hallucinations: visual or auditory disturbances, especially in older patients. - Orthostatic hypotension: drop in blood pressure upon standing. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Severe liver injury: elevated transaminases requiring monitoring. - Agranulocytosis: marked reduction in white blood cells. - Neuroleptic malignant syndrome: life‑threatening hyperthermia and rigidity. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Dyskinesia: involuntary movements with high dopaminergic exposure. - Hyperthermia: unexplained high fever requiring urgent care.

When prescribing Lecigimon, clinicians should consider several safety measures.

- Monitor blood pressure: check for orthostatic hypotension, especially after dose initiation. - Assess hepatic function: obtain baseline liver enzymes and repeat periodically. - Evaluate psychiatric status: watch for new or worsening hallucinations or confusion. - Adjust dose in renal impairment: consider reduced dosing in patients with decreased clearance. - Avoid use in narrow‑angle glaucoma: the drug may increase intra‑ocular pressure. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Lecigimon can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Anticholinergic agents: may worsen Parkinsonian symptoms. - CNS depressants: increased sedation and respiratory depression.

Moderate Interactions (Monitor Closely): - SSRIs or SNRIs: potential for serotonin syndrome. - Diuretics: may enhance orthostatic hypotension. - Antihypertensive drugs: may require dose adjustment to avoid excessive blood pressure drop.